Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 17.
doi: 10.1038/s41372-024-02201-0. Online ahead of print.

Nebulized salbutamol for the treatment of transient tachypnea of the newborn: a randomized controlled trial

Aditi Dhaka  1   2 , Sonu Kumar  1 , Poonam Singh  1 , Mayank Priyadarshi  1 , Suman Chaurasia  1 , Nowneet Kumar Bhat  2 , Sriparna Basu  3
Affiliations

Nebulized salbutamol for the treatment of transient tachypnea of the newborn: a randomized controlled trial

Aditi Dhaka et al. J Perinatol. .

Abstract

Objective: To compare the efficacy of nebulized salbutamol in reducing respiratory distress in late preterm and term neonates with transient tachypnea of newborn (TTN).

Study design: Double-blind, placebo-controlled randomized trial.

Methods: Neonates with TTN (n = 134) were allocated to nebulized salbutamol (n = 67) versus placebo (normal saline) (n = 67). The primary outcome was the duration of tachypnea (respiratory rate >60/min). Secondary outcomes were maximum Downes score and fraction of inspired oxygen (FiO2) after nebulization, duration of respiratory support, and adverse effects of salbutamol nebulization.

Results: Median duration of tachypnea was 12.5 (10-16) vs. 12 (10.4-14) hours in salbutamol and placebo groups, respectively; p = 0.489. Almost all neonates received positive-pressure respiratory support at delivery room and subsequently. Maximum Downe's score, FiO2 requirement, and duration of respiratory support were similar. No adverse effect of salbutamol was documented.

Conclusion: There was no difference in the duration of tachypnea with nebulized salbutamol compared to placebo in late preterm and term neonates with TTN.

Clinical trial registration: Clinical trial registry of India, Registration no: CTRI/2023/05/052441, Registered prospectively on 10/05/2023, https://ctri.icmr.org.in/.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests. Ethics approval: This study was performed in line with the principles of the Declaration of Helsinki. The study protocol was approved by the Institute’s Ethics Committee of AIIMS Rishikesh, Uttarakhand, India (Ref No: AIIMS/IEC/23/143, dated 28/04/2023). Consent to participate: Written informed consent was obtained from the parents of each subject before enrolment. Consent for publication: Patients signed informed consent regarding publishing their data and photographs.

Similar articles

See all similar articles

References

    1. Clark RH. The epidemiology of respiratory failure in neonates born at an estimated gestational age of 34 weeks or more. J Perinatol. 2005;25:251–7. - DOI - PubMed
    1. Edwards MO, Kotecha SJ, Kotecha S. Respiratory distress of the term newborn infant. Paediatr Respir Rev. 2013;14:29–36. - DOI - PubMed
    1. Hansen AK, Wisborg K, Uldbjerg N, Henriksen TB. Risk of respiratory morbidity in term infants delivered by elective caesarean section: cohort study. BMJ. 2008;336:85–7. - DOI - PubMed
    1. Hagen E, Chu A, Lew C. Transient tachypnea of the newborn. NeoReviews. 2017;18:e141. - DOI
    1. Liem JJ, Huq SI, Ekuma O, Becker AB, Kozyrskyj AL. Transient tachypnea of the newborn may be an early clinical manifestation of wheezing symptoms. J Pediatr. 2007;151:29–33. - DOI - PubMed

LinkOut - more resources